Antileukemic effects of novel immunomodulatory agent lenalinomide (L) with or without rituximab (R) in patients (pts) with relapsed (rel) or refractory (ref) chronic lymphocytic leukemia (CLL). Encouraging preliminary results of an ongoing phase II clinical study

Miller, Kena C.; Czuczman, Myron S.; DiMiceli, Laurie; McCarthy, Philip L.; Bernstein, Zale P.; Zeldis, Jerome B.; Mohr, Alice; Chanan‐Khan, Asher

doi:10.1200/jco.2005.23.16_suppl.6557

Cited by 6 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There were additional abstracts confirming earlier reports of high RRs for thalidomide and dexamethasone in newly diagnosed myeloma prior to autologous transplant [77] and compared with melphalan and prednisone [78]. Results in solid tumours were less encouraging.…”

Section: Thalmidssupporting

confidence: 67%

American Society of Clinical Oncology 41st Annual Meeting

Dillman

2005

Expert Opinion on Biological Therapy

View full text Add to dashboard Cite

For many years the annual meeting of the American Society of Clinical Oncology (ASCO) has been the premier meeting in clinical oncology, and one that is closely scrutinised by Wall Street and international investors because of the economic significance of cancer therapies to the pharmaceutical and biotechnology industries. The area of biologicals and targeted therapies exploded in the late 1990s after the blockbuster results with the monoclonal antibody rituximab in the treatment of lymphoma. Although historically a somewhat conservative organisation that is still closely tied to classical cytotoxic chemotherapy, ASCO has been able to integrate various areas of biological therapy into its scope of clinical activity. Although ASCO still has 'American' in its title, it is really the 'International' Society of Clinical Oncology, as reflected by the attendance at this year's meeting by approximately 30,000, with approximately two-thirds attending from outside the US. There were 9708 abstracts published in conjunction with the meeting, 86 of which are referenced in this review. There were 10 papers chosen for plenary presentations and many other key papers were presented at other oral abstract sessions and poster discussion session that were organised by tumour type. In addition to key papers submitted by specific tumour type, for this year's meeting there were 103 abstracts published in the session entitled 'Developmental Therapeutics: Immunotherapy', and 218 in the session entitled Developmental Therapeutics: Molecular Targets', for a total of 321 biological therapy abstracts compared with only 125 abstracts for the session entitled 'Developmental Therapeutics: Cytotoxic Therapy'. This meeting review is organised by biotherapy modality rather than tumour type.

show abstract